18/02/2026
KEMRI is excited to be part of Kenya’s mRNA vaccine manufacturing journey
Today, the Principal Secretary for Medical Services, Dr. Ouma Oluga, officially launched Kenya’s participation in the WHO–Medicines Patent Pool (MPP) mRNA Technology Transfer Programme — a landmark step toward strengthening national and regional health security.
Through collaboration with the Kenya BioVax Institute Limited, KEMRI will contribute its research expertise and laboratory infrastructure to support the establishment of sustainable, locally owned mRNA vaccine and biopharmaceutical manufacturing capacity.
The programme positions Kenya among a select group of countries building capability for future vaccines and therapeutics targeting priority diseases
The launch brought together representatives from WHO Kenya and the Meds Patent Pool, leadership of Kenya BioVax Institute Limited (KBI) and KEMRI led by Ag. Director General represented by Ms. Lilian Mayieka, the Pharmacy and Poisons Board, development partners, and industry stakeholders, including Thermo Fisher Scientific.